肺癌患者的程序性死亡受体配体1（PD-L1）状态与生存情况——回复 - Suppr

Suppr

超能文献

PD-L1 Status and Survival in Patients With Lung Cancer-Reply.

作者信息

Miller Peter Grant, Li Gerald, Singal Gaurav

机构信息

Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts.

Foundation Medicine Inc, Cambridge, Massachusetts.

出版信息

JAMA. 2019 Aug 27;322(8):783-784. doi: 10.1001/jama.2019.9196.

DOI:10.1001/jama.2019.9196

PMID:31454037

Abstract

摘要

相似文献

PD-L1 Status and Survival in Patients With Lung Cancer-Reply.肺癌患者的程序性死亡受体配体1（PD-L1）状态与生存情况——回复

JAMA. 2019 Aug 27;322(8):783-784. doi: 10.1001/jama.2019.9196.

PD-L1 Status and Survival in Patients With Lung Cancer.

JAMA. 2019 Aug 27;322(8):783. doi: 10.1001/jama.2019.9177.

Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.PD-L1表达及PD-L1基因多态性与肺腺癌和肺鳞癌预后不良的相关性

Hum Pathol. 2017 Oct;68:103-111. doi: 10.1016/j.humpath.2017.08.016. Epub 2017 Aug 26.

Programmed Death Cell Ligand 1 (PD-L1) Is Associated With Survival in Stage I Non-Small Cell Lung Cancer.程序性死亡细胞配体1（PD-L1）与I期非小细胞肺癌的生存率相关。

Semin Thorac Cardiovasc Surg. 2017;29(3):408-415. doi: 10.1053/j.semtcvs.2017.05.008. Epub 2017 May 26.

Prognostic Significance of Programmed Cell Death Ligand 1 (PD-L1), CD8+ Tumor-Infiltrating Lymphocytes and p53 in Non-Small Cell Lung Cancer: An Immunohistochemical Study.程序性细胞死亡配体1（PD-L1）、CD8 +肿瘤浸润淋巴细胞和p53在非小细胞肺癌中的预后意义：一项免疫组织化学研究

Turk Patoloji Derg. 2017;1(1):211-222. doi: 10.5146/tjpath.2017.01398.

[The expression of PD-L1 in the non-small cell lung cancer and the correlation with the novel lung adenocarcinoma classification].

Zhonghua Bing Li Xue Za Zhi. 2020 Jun 8;49(6):607-609. doi: 10.3760/cma.j.cn112151-20191015-00561.

Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma.显著核仁与非腺特征是肺腺癌中PD-L1表达的独立预测因素。

Anticancer Res. 2018 Oct;38(10):6003-6008. doi: 10.21873/anticanres.12949.

Programmed death-ligand 1 expression associated with molecular characteristics in surgically resected lung adenocarcinoma.程序性死亡配体1表达与手术切除肺腺癌的分子特征相关。

J Transl Med. 2016 Jun 24;14(1):188. doi: 10.1186/s12967-016-0943-4.

Programmed Death-Ligand 1 Expression Predicts Tyrosine Kinase Inhibitor Response and Better Prognosis in a Cohort of Patients With Epidermal Growth Factor Receptor Mutation-Positive Lung Adenocarcinoma.程序性死亡配体1表达可预测表皮生长因子受体突变阳性肺腺癌患者队列中酪氨酸激酶抑制剂的反应及更好的预后。

Clin Lung Cancer. 2015 Sep;16(5):e25-35. doi: 10.1016/j.cllc.2015.02.002. Epub 2015 Feb 19.

PD-L1 expression and tumor mutational burden status for prediction of response to chemotherapy and targeted therapy in non-small cell lung cancer.程序性死亡配体 1 表达和肿瘤突变负担状态预测非小细胞肺癌对化疗和靶向治疗的反应。

J Exp Clin Cancer Res. 2019 May 14;38(1):193. doi: 10.1186/s13046-019-1192-1.

引用本文的文献

The role of nursing in enhancing quality of life for lung cancer patients receiving targeted and immunotherapy: Challenges, opportunities, and future directions.护理在提高接受靶向治疗和免疫治疗的肺癌患者生活质量中的作用：挑战、机遇与未来方向。

Hum Vaccin Immunother. 2025 Dec;21(1):2506302. doi: 10.1080/21645515.2025.2506302. Epub 2025 May 20.

Neoadjuvant pembrolizumab with chemotherapy for the treatment of stage IIB-IIIB resectable lung squamous cell carcinoma.新辅助派姆单抗联合化疗治疗IIB-IIIB期可切除肺鳞状细胞癌

J Thorac Dis. 2021 Mar;13(3):1760-1768. doi: 10.21037/jtd-21-103.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验